XORTX Therapeutics Inc. (XRTX)
Develops medicines to treat kidney disease and gout by lowering uric acid levels.
$2.05+0.00%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-43.5%
The outlook
XRTX is trading near its 52-week low, well below both its 50- and 200-day moving averages, signaling a downtrend. Analyst coverage appears thin or absent. The stock sits in the lower end of its annual range, reflecting weak momentum.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range6% of the way from its 52-week low to high
Market cap
$3.5M
52-wk high
$7.05
52-wk low
$1.73
50-day avg
$2.17
200-day avg
$2.58
Trailing P/E
—